Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Ann Oncol ; 28(10): 2503-2510, 2017 Oct 01.
Article in English | MEDLINE | ID: mdl-28945825

ABSTRACT

BACKGROUND: Most patients with multiple myeloma (MM) are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among these patients. Therefore, new technologies to assess deeper response are required. PATIENTS AND METHODS: We retrospectively analyzed 125 patients with MM who underwent high-dose melphalan plus autologous stem-cell transplantation (ASCT) to detect MRD in autograft/bone marrow (BM) cells using a next-generation sequencing (NGS)-based method and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR). RESULTS: NGS-based method was applicable to 90% and this method had at least one to two logs greater sensitivity compared to ASO-PCR. MRD negative by NGS [MRDNGS(-)] (defined as <10-6) in post-ASCT BM cases (n = 26) showed a significantly better progression-free survival (PFS) (96% at 4 years, P < 0.001) and overall survival (OS) (100% at 4 years, P =0.04) than MRDNGS(+) in post-ASCT BM cases (n = 25). When restricting the analysis to the 39 complete response cases, patients who were MRDNGS(-) (n = 24) showed a significantly better PFS than those that were MRDNGS(+) (n = 15) (P =0.02). Moreover, MRDNGS(-) in post-ASCT BM cases (n = 12) showed significantly a better PFS than MRDNGS(+) cases (n = 7) where MRD was not detected by ASO-PCR (P = 0.001). Patients whose autografts were negative by NGS-based MRD assessment (<10-7) (n = 19) had 92% PFS and 100% OS at 4 years post-ASCT. Conversely, the NGS-based MRD positive patients who received post-ASCT treatment using novel agents (n = 49) had a significantly better PFS (P = 0.001) and tended to have a better OS (P= 0.214) than those that were untreated (n = 33). CONCLUSIONS: Low level MRD detected by NGS-based platform but not ASO-PCR has significant prognostic value when assessing either the autograft product or BM cells post-ASCT.


Subject(s)
Bone Marrow Transplantation/methods , Melphalan/therapeutic use , Multiple Myeloma/genetics , Multiple Myeloma/therapy , Stem Cell Transplantation/methods , Antineoplastic Agents, Alkylating/therapeutic use , Disease-Free Survival , High-Throughput Nucleotide Sequencing/methods , Humans , Multiple Myeloma/drug therapy , Neoplasm, Residual/genetics , Polymerase Chain Reaction/methods , Prognosis , Retrospective Studies , Transplantation, Autologous , Treatment Outcome
3.
Leukemia ; 27(8): 1659-65, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23419792

ABSTRACT

Quantification of minimal residual disease (MRD) following allogeneic hematopoietic cell transplantation (allo-HCT) predicts post-transplant relapse in patients with chronic lymphocytic leukemia (CLL). We utilized an MRD-quantification method that amplifies immunoglobulin heavy chain (IGH) loci using consensus V and J segment primers followed by high-throughput sequencing (HTS), enabling quantification with a detection limit of one CLL cell per million mononuclear cells. Using this IGH-HTS approach, we analyzed MRD patterns in over 400 samples from 40 CLL patients who underwent reduced-intensity allo-HCT. Nine patients relapsed within 12 months post-HCT. Of the 31 patients in remission at 12 months post-HCT, disease-free survival was 86% in patients with MRD <10(-4) and 20% in those with MRD ≥10(-4) (relapse hazard ratio (HR) 9.0; 95% confidence interval (CI) 2.5-32; P<0.0001), with median follow-up of 36 months. Additionally, MRD predicted relapse at other time points, including 9, 18 and 24 months post-HCT. MRD doubling time <12 months with disease burden ≥10(-5) was associated with relapse within 12 months of MRD assessment in 50% of patients, and within 24 months in 90% of patients. This IGH-HTS method may facilitate routine MRD quantification in clinical trials.


Subject(s)
Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Neoplasm, Residual/diagnosis , Neoplasm, Residual/genetics , Adult , Aged , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation , High-Throughput Nucleotide Sequencing , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Prognosis , Recurrence , Reproducibility of Results , Time Factors
4.
Appl Opt ; 35(19): 3478-87, 1996 Jul 01.
Article in English | MEDLINE | ID: mdl-21102738

ABSTRACT

Three-dimensional (3D) concentrators for photomultipliers with curved photocathodes have been designed by taking the figures of revolution of ideal two-dimensional (2D) concentrators that are constructed from the 2D profiles of the photocathodes. Two new arguments are presented as to why these 3D concentrators cannot quite reach the maximum concentration factor allowed by the conservation of phase space. Improvements in performance have been obtained by optimizing the collection of off-axis rays and filling the concentrator with a dielectric of suitable refractive index. The complicated optical behavior of the photocathode does not affect concentrator performance.

SELECTION OF CITATIONS
SEARCH DETAIL
...